Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are approved for treating type 2 diabetes and weight loss
Hevener, A
While many have action plans with testing and treatment policies, large-scale HBV testing policies are lacking, and treatment barriers remain
A 2024 study from the International Foundation of Employee Benefit Plans showed that employer coverage of GLP-1s is still limited, with 34% of corporate plans currently providing coverage for non-diabetic patients who want to lose weight (up 8 percentage points from 2023)
The immunometabolic mechanisms of curcumin suggest that benefit would be concentrated in the former subgroup, and stratified trial designs testing this hypothesis would generate actionable responder profiles
Abbreviations GCGR: Glucagon receptor GIP: Glucose-dependent insulinotropic polypeptide GIPR: Glucose-dependent insulinotropic polypeptide receptor GLP-1: Glucagon-like peptide-1 GLP-1R: Glucagon-like peptide-1 receptor NAFLD: Non-alcoholic fatty liver disease NASH: Non-alcoholic steatohepatitis STEP: Semaglutide Treatment Effect in People with Obesity References Bray GA, Kim KK, Wilding JPH (2017) Obesity: a chronic relapsing progressive disease process
